Candel Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for CAN-3110 -- a first-in-class, replication-competent herpes simplex virus-1 (HSV-1) oncolytic viral immunotherapy candidate ? for the treatment of patients with recurrent high-grade glioma (HGG) to improve overall survival.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.97 USD | -7.94% | +18.27% | +578.23% |
Apr. 11 | Sector Update: Health Care Stocks Decline Thursday Afternoon | MT |
Apr. 11 | Candel Therapeutics Shares Rise After FDA Orphan Drug Designation for Potential Pancreatic Cancer Drug | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+578.23% | 318M | |
+23.37% | 46.71B | |
+48.83% | 41.8B | |
-0.94% | 41.52B | |
-5.86% | 29.55B | |
+11.29% | 25.78B | |
-20.92% | 19.26B | |
+3.20% | 12.14B | |
-2.67% | 12.08B | |
+30.23% | 11.98B |
- Stock Market
- Equities
- CADL Stock
- News Candel Therapeutics, Inc.
- Candel Therapeutics, Inc.'s CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma